Allena Pharmaceuticals (ALNAQ) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 12, 2022
Entity Addresses [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	ALNA
Entity Registrant Name	ALLENA PHARMACEUTICALS, INC.
Entity Central Index Key	0001624658
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		122,083,226
Entity File Number	001-38268
Entity Tax Identification Number	45-2729920
Entity Address, Address Line One	142-F North Road
Entity Address, Address Line Two	Suite 150
Entity Address, City or Town	Sudbury
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01776
City Area Code	617
Local Phone Number	467-4577
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	DE
Former Address
Entity Addresses [Line Items]
Entity Address, Address Line One	One Newton Executive Park
Entity Address, Address Line Two	Suite 202
Entity Address, City or Town	Newton
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02462

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 6,589	$ 29,988
Prepaid expenses and other current assets	9,897	3,018
Total current assets	16,486	33,006
Property and equipment, net	930	1,173
Operating lease assets	272	455
Other assets	123	123
Total assets	17,811	34,757
Current liabilities:
Accounts payable	2,271	1,030
Loan payable, net of discount	4,904	9,852
Accrued expenses and other current liabilities	2,870	4,480
Operating lease liabilities, net of discount	380	317
Total current liabilities	10,425	15,679
Warrant liability	3,645
Operating lease liabilities, net of current portion and discount		210
Total liabilities	14,070	15,889
Commitments and contingencies (Note 6)
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value; 5,000,000 shares authorized; 2,872 shares issued and no shares outstanding at June 30, 2022; no shares issued and outstanding at December 31, 2021
Common stock, $0.001 par value; 200,000,000 shares authorized; 107,725,169 and 82,969,421 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	108	83
Additional paid-in capital	270,333	265,237
Accumulated deficit	(266,700)	(246,452)
Total stockholders’ equity	3,741	18,868
Total liabilities and stockholders’ equity	$ 17,811	$ 34,757

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Undesignated preferred stock, par value	$ 0.001	$ 0.001
Undesignated preferred stock, shares authorized	5,000,000	5,000,000
Undesignated preferred stock, shares issued	2,872	0
Undesignated preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	107,725,169	82,969,421
Common stock, shares outstanding	107,725,169	82,969,421

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 3,981	$ 10,090	$ 11,739	$ 17,942
General and administrative	2,943	3,597	6,742	7,155
Total operating expenses	6,924	13,687	18,481	25,097
Loss from operations	(6,924)	(13,687)	(18,481)	(25,097)
Other income (expense):
Loss on issuance of securities	(371)		(371)
Change in valuation of warrant liability	(1,023)		(1,023)
Interest expense, net	(118)	(253)	(367)	(488)
Other income (expense), net	1	(32)	(6)	(23)
Other expense, net	(1,511)	(285)	(1,767)	(511)
Net loss	$ (8,435)	$ (13,972)	$ (20,248)	$ (25,608)
Net loss per share attributable to common stockholders-basic	$ (0.08)	$ (0.24)	$ (0.21)	$ (0.45)
Net loss per share attributable to common stockholders-diluted	$ (0.08)	$ (0.24)	$ (0.21)	$ (0.45)
Weighted-average common share outstanding-basic	100,623,730	57,932,389	95,034,212	56,484,811
Weighted-average common share outstanding-diluted	100,623,730	57,932,389	95,034,212	56,484,811
Comprehensive loss	$ (8,435)	$ (13,972)	$ (20,248)	$ (25,608)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Series D Convertible Preferred Stock	Series E Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Dec. 31, 2020	$ 22,569			$ 51	$ 220,307	$ (197,789)
Balance, Shares at Dec. 31, 2020				50,821,361
Balance at Mar. 31, 2021	23,503			$ 57	232,871	(209,425)
Balance, Shares at Mar. 31, 2021				56,879,679
Balance at Dec. 31, 2020	22,569			$ 51	220,307	(197,789)
Balance, Shares at Dec. 31, 2020				50,821,361
Issuance of common stock, net of issuance costs	13,474			$ 8	13,466
Issuance of common stock, net of issuance costs, shares				7,709,306
Issuance of common stock through employee stock purchase plan ("ESPP")	5				5
Issuance of common stock through employee stock purchase plan ("ESPP"), shares				4,206
Issuance of common stock through release of restricted stock units ("RSUs"), shares				248,111
Stock-based compensation	1,827				1,827
Net loss	(25,608)					(25,608)
Balance at Jun. 30, 2021	12,267			$ 59	235,605	(223,397)
Balance, Shares at Jun. 30, 2021				58,782,984
Balance at Mar. 31, 2021	23,503			$ 57	232,871	(209,425)
Balance, Shares at Mar. 31, 2021				56,879,679
Issuance of common stock, net of issuance costs	1,771			$ 2	1,769
Issuance of common stock, net of issuance costs, shares				1,650,988
Issuance of common stock through employee stock purchase plan ("ESPP")	5				5
Issuance of common stock through employee stock purchase plan ("ESPP"), shares				4,206
Issuance of common stock through release of restricted stock units ("RSUs"), shares				248,111
Stock-based compensation	960				960
Net loss	(13,972)					(13,972)
Balance at Jun. 30, 2021	12,267			$ 59	235,605	(223,397)
Balance, Shares at Jun. 30, 2021				58,782,984
Balance at Dec. 31, 2021	$ 18,868			$ 83	265,237	(246,452)
Balance, Shares at Dec. 31, 2021	82,969,421			82,969,421
Balance at Mar. 31, 2022	$ 11,616			$ 90	269,791	(258,265)
Balance, Shares at Mar. 31, 2022				89,774,309
Balance at Dec. 31, 2021	$ 18,868			$ 83	265,237	(246,452)
Balance, Shares at Dec. 31, 2021	82,969,421			82,969,421
Issuance of convertible preferred stock and warrants, net of issuance costs, shares		1,436	1,436
Conversion of preferred stock into common stock				$ 18	(18)
Conversion of preferred stock into common stock, shares		(1,436)	(1,436)	17,950,860
Issuance of common stock, net of issuance costs	$ 3,944			$ 7	3,937
Issuance of common stock, net of issuance costs, shares				6,804,888
Stock-based compensation	1,177				1,177
Net loss	(20,248)					(20,248)
Balance at Jun. 30, 2022	$ 3,741			$ 108	270,333	(266,700)
Balance, Shares at Jun. 30, 2022	107,725,169			107,725,169
Balance at Mar. 31, 2022	$ 11,616			$ 90	269,791	(258,265)
Balance, Shares at Mar. 31, 2022				89,774,309
Issuance of convertible preferred stock and warrants, net of issuance costs, shares		1,436	1,436
Conversion of preferred stock into common stock				$ 18	(18)
Conversion of preferred stock into common stock, shares		(1,436)	(1,436)	17,950,860
Stock-based compensation	560				560
Net loss	(8,435)					(8,435)
Balance at Jun. 30, 2022	$ 3,741			$ 108	$ 270,333	$ (266,700)
Balance, Shares at Jun. 30, 2022	107,725,169			107,725,169

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (20,248)	$ (25,608)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,177	1,827
Depreciation expense	243	145
Loss on issuance of securities	371
Change in valuation of warrant liability	1,023
Non-cash interest expense	52	27
Non-cash lease expense	189	190
Changes in assets and liabilities:
Prepaid expenses and other current assets	(6,879)	542
Other assets		(50)
Accounts payable	1,241	124
Accrued expenses	(1,610)	1,555
Operating lease liabilities	(153)	(150)
Net cash used in operating activities	(24,594)	(21,398)
Cash flows from investing activities:
Purchases of property and equipment		(457)
Net cash used in investing activities		(457)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	3,944	13,464
Proceeds from the issuance of convertible preferred stock, net of issuance costs	2,251
Proceeds from issuance of stock through ESPP		5
Repayment of loan payable	(5,000)
Net cash provided by financing activities	1,195	13,469
Net decrease in cash and cash equivalents	(23,399)	(8,386)
Cash and cash equivalents, beginning of period	29,988	35,042
Cash and cash equivalents, end of period	$ 6,589	26,656
Supplemental disclosures:
Issuance costs included in accounts payable and accrued expenses		$ 10

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	1. Nature of Business Allena Pharmaceuticals, Inc. (the “Company”) is a clinical stage company focused on developing non-absorbed oral enzyme therapeutics to treat metabolic conditions including hyperuricemia and gout. The Company was incorporated under the laws of the State of Delaware on June 24, 2011. The Company’s headquarters are in Sudbury, Massachusetts. The Company is subject to risks common to companies in the biotechnology industry, including but not limited to, risks of failure of preclinical studies and clinical trials, the need to obtain marketing approval for any drug product candidate that it may identify and develop, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations, reliance on third party manufacturers, ability to transition from pilot-scale manufacturing to large-scale production of products and the need to obtain adequate additional financing to fund the development of its product candidates. Liquidity and Going Concern The Company had an accumulated deficit of $ 266.7 million at June 30, 2022 and will require substantial additional capital to fund operations. The future success of the Company is dependent on its ability to identify and develop its product candidates and ultimately upon its ability to attain profitable operations. At June 30, 2022, the Company had $ 6.6 million of cash and cash equivalents. The Company’s available cash and cash equivalents as of June 30, 2022 are not sufficient to fund the Company’s current operating plan for at least the next twelve months following the filing of this Quarterly Report. The Company requires additional capital to sustain its operations, including its ALLN-346 development program. Management is exploring opportunities to secure additional funding through equity or debt financings or through collaborations, licensing transactions or other sources. In January 2022, the Company initiated a process to explore a range of strategic and financing alternatives to maximize stockholder value and has engaged the investment bank Stifel, Nicolaus & Company, Inc. ("Stifel") to act as strategic advisor for this process. Potential strategic alternatives that may be evaluated include a partnership or sale of ALLN-346, a sale or merger of the Company, or securing additional financing to enable further development of the Company's ALLN-346 program. There can be no assurance that this strategic review process will result in the Company pursuing any transaction or that any transaction, if pursued, will be completed. If the Company is unable to complete a transaction, it may be required to seek an in-court or out-of-court restructuring of its liabilities. As part of the strategic process, the Compensation Committee of the Board of Directors approved a retention plan on January 28, 2022, available to all employees (the "Retention Plan"). Employees were required to execute retention agreements to receive payments and other considerations offered by the Retention Plan. Employees who executed a retention agreement received a salary adjustment equal to 6.5 % retroactive to January 1, 2022, a restricted stock unit ("RSU") grant and a lump sum retention payment. A total of 2,998,500 RSUs were granted on February 1, 2022 under the Retention Plan. Lump sum retention payments totaling $ 3.0 million were made to employees in February 2022. If an employee resigns from the Company or is terminated for cause prior to June 30, 2022, the employee would be required to fully repay the lump sum retention payment received. If an employee resigns from the Company or is terminated for cause between July 1, 2022 and September 30, 2022, the employee would be required to repay 50 % of the lump sum retention payment received. During the first quarter of 2022, the Company made voluntary principal repayments of $ 5.0 million of the $ 10.0 million that was outstanding as of December 31, 2021 under the loan and security agreement with Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P. (together “Pontifax”) (the “Pontifax Agreement”). The Company made an additional voluntary principal repayment of $ 0.5 million in August 2022. The outstanding principal balance as of the filing date of this Quarterly Report is $ 4.5 million. The Company also purchased Directors' & Officers' run-off insurance for $ 6.8 million in March 2022. On March 18, 2022, the Company announced that it was terminating its URIROX-2 study and reloxaliase program and initiated the process of closing the URIROX-2 study with the CRO, investigative sites, patients and business partners. In connection with the termination of the reloxaliase program, the Company completed a workforce reduction of approximately 40 % on March 31, 2022. In accordance with the terms of the Retention Plan, the employees terminated by the Company on March 31, 2022 were not required to repay any portion of their lump sum retention payments originally received in February 2022. During the first quarter of 2022, the Company issued and sold 6,804,888 shares of its common stock under an At-Market Issuance Sales Agreement with B. Riley Securities, Inc. at a weighted average price of $ 0.62 per share for net proceeds of $ 3.9 million. On May 3, 2022, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company agreed to issue, in a registered direct offering, an aggregate of 2,872.1376 shares of Preferred Stock (split evenly between the Series D Convertible Preferred Stock, par value $ 0.001 per share (“Series D Preferred Stock”), and Series E Convertible Preferred Stock, par value $ 0.001 per share (“Series E Preferred Stock” and together with the Series D Preferred Stock, the “Preferred Stock”)). The Company received net proceeds of approximately $ 2.3 million from the issuance and sale of the Preferred Stock, after deducting offering expenses and placement agent fees. The shares of Preferred Stock have a stated value of $ 1,000 per share and are convertible, following the date of the issuance thereof, into an aggregate of 8,975,430 shares of common stock of the Company upon the conversion of the Series D Preferred Stock and into an aggregate of 8,975,430 shares of common stock of the Company upon the conversion of the Series E Preferred Stock, in each case, at a conversion price of $ 16.00 per share. H.C. Wainwright & Co., LLC (“HCW”) was the exclusive placement agent for this offering. On May 5, 2022, the Preferred Stock investor converted all of its Series D Preferred Stock into 8,975,430 shares of common stock, and on May 9, 2022, the Preferred Stock investor converted all of its Series E Preferred Stock into 8,975,430 shares of common stock. In a concurrent private placement, the Company also issued to the Preferred Stock investor unregistered warrants (the “2022 Common Warrants”) to purchase up to an aggregate of 22,438,575 shares of the Company’s common stock, at an exercise price of $ 0.1694 per share. The 2022 Common Warrants will become exercisable six months after the date of issuance, and will have a term of five years from the initial exercise date. The Company also issued to designees of HCW, in a concurrent private placement, warrants to purchase up to 1,256,561 shares of Common Stock (the “HCW Warrants”). The HCW Warrants are exercisable for $ 0.20 per share and will be exercisable six months after the date of issuance and have a term of five years from the commencement of sales pursuant to the registered direct offering. The Company entered into an At Market Offering Agreement with H.C. Wainwright & Co., LLC (“HCW ATM Agreement”) on July 8, 2022. Since that time and through the filing date of this Quarterly Report, the Company issued and sold 14,358,057 shares of its common stock under the HCW ATM Agreement at a weighted average price of $ 0.14 per share for net proceeds of approximately $ 1.9 million. Reverse Stock Split At a special meeting of stockholders held on August 4, 2022, the Company’s stockholders approved an amendment to the Company’s amended and restated certificate of incorporation, as amended, to, at the discretion of the Company’s board of directors, effect a reverse stock split with respect to its issued and outstanding Common Stock, par value $ 0.001 per share, including any Common Stock held by the Company as treasury shares, at any time prior to December 31, 2022, at a ratio of 1-for-10 to 1-for-100 (the “Range”). The Range and timing of the reverse stock split will be determined by the Company’s board of directors without further approval or authorization of the Company’s stockholders and included in a public announcement once determined.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of June 30, 2022, the results of its operations and cash flows for the three and six months ended June 30, 2022 and June 30, 2021 and cash flows for the six months ended June 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022 or for any future period. Principles of Consolidation The consolidated financial statements include the accounts of Allena Pharmaceuticals, Inc. and its wholly owned subsidiaries Allena Pharmaceuticals Security Corporation (“Security Corporation”), which was incorporated in December 2014 , and Allena Pharmaceuticals Ireland Limited, which was incorporated in March 2017 . All intercompany transactions and balances have been eliminated. Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: Level 1 inputs: Quoted prices in active markets for identical assets or liabilities. Level 2 inputs: Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The remainder of the Company’s significant accounting policies are described in the Annual Report filed on Form 10-K for the year ended December 31, 2021 that was filed with the United States Securities and Exchange Commission on March 31, 2022. Warrants The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. Recently Adopted Accounting Pronouncements In 2020, the FASB issued ASU 2020-06, Debt -Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) , which simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU also simplify the guidance in ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The Company adopted ASU 2020-06 on January 1, 2022 . The adoption of ASU 2020-06 did not have a material impact on the Company's condensed consolidated financial statements. Recently Issued Accounting Pronouncements In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for smaller reporting companies on January 1, 2023. Early adoption is permitted. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its condensed consolidated financial statements.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss per Share	3. Net Loss per Share Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities. The Company has computed diluted net loss per common share after giving consideration to all potentially dilutive common shares, including options to purchase common stock, restricted stock units, common stock issuable upon conversion of outstanding debt and warrants to purchase common stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential common shares have been anti-dilutive and basic and diluted loss per share have been the same. Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 8,435 ) $ ( 13,972 ) $ ( 20,248 ) $ ( 25,608 ) Net loss attributable to common stockholders $ ( 8,435 ) $ ( 13,972 ) $ ( 20,248 ) $ ( 25,608 ) Denominator: Weighted-average common shares—basic and diluted 100,623,730 57,932,389 95,034,212 56,484,811 Net loss per share attributable to common $ ( 0.08 ) $ ( 0.24 ) $ ( 0.21 ) $ ( 0.45 ) The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares): Six Months Ended June 30, 2022 2021 Stock options 5,435,949 7,091,757 Restricted stock units 2,093,500 372,166 Warrants 34,383,048 9,040 Common stock issuable upon conversion of outstanding debt 1,219,512 2,439,024 Total 43,132,009 9,911,987

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value at June 30, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): Description June 30, Quoted Significant Significant Assets: Money market funds, included in cash and cash equivalents $ 5,589 $ 5,589 $ — $ — Total assets $ 5,589 $ 5,589 $ — $ — Liabilities: Warrant liability $ 3,645 $ — $ — $ 3,645 Total liabilities $ 3,645 $ — $ — $ 3,645 Description December 31, Quoted Significant Significant Assets: Money market funds, included in cash and cash equivalents $ 16,523 $ 16,523 $ — $ — Total assets $ 16,523 $ 16,523 $ — $ — At June 30, 2022 and December 31, 2021, all of the Company’s cash equivalents were comprised of money market funds. There were no changes to the valuation methods during the six months ended June 30, 2022 and year ended December 31, 2021. There were no transfers within the fair value hierarchy during the six months ended June 30, 2022 and the year ended December 31, 2021. The carrying amounts reflected in the consolidated balance sheets for cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values. Assumptions Used in Determining Fair Value of Warrants The Company issued the 2022 Common Warrants and the HCW Warrants to purchase an aggregate of up to 23,695,136 shares of common stock in connection with a registered direct financing on May 4, 2022 (see Note 8). The Company concluded that the warrants are not indexed to its own stock and therefore the 2022 Common Warrants and the HCW Warrants are being accounted for as liabilities. The Company recorded the fair value of the warrants upon issuance using the Black-Scholes valuation model and is required to revalue the warrants at each reporting date with any changes in fair value recorded on the statement of operations. The valuation of the warrants is considered under Level 3 of the fair value hierarchy and influenced by the fair value of the underlying common stock of the Company. A summary of the Black Scholes pricing model assumptions used to record the fair value of the warrants is as follows: June 30, 2022 May 4, 2022 Stock price $ 0.19 $ 0.14 Risk-free interest rate 3.01 % 2.93 % Expected dividend yield —% —% Expected term (in years) 4.9 - 5.4 5.0 - 5.5 Expected volatility 106 % 105 % Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis The following table reflects the change in the Company’s Level 3 Warrant liability for the six months ended June 30, 2022 (in thousands): Fair value of warrant liability as of the beginning of the period $ — Issuance of warrants 2,622 Change in fair value 1,023 Fair value of warrant liability as of the end of the period $ 3,645

Accrued Expenses

Accrued Expenses	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Accrued Expenses	5. Accrued Expenses Accrued expenses consist of the following (in thousands): June 30, December 31, Payroll and employee-related expenses $ 295 $ 371 Third-party research and development expenses 2,260 3,195 Professional fees 184 677 Loan interest 112 227 Other 19 10 Total accrued expenses $ 2,870 $ 4,480

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies The Company is a party to an operating lease for approximately 11,691 square feet of laboratory and office space in Sudbury, MA (Sudbury Lease). The Sudbury Lease expires on February 28, 2026 . The Company has a one-time option to cancel the lease effective February 28, 2023 for any reason or no reason at all . Annualized base rent for the Sudbury lease is approximately $ 0.3 million. Maturities of the Company’s operating lease liabilities in accordance with ASC 842 as of June 30, 2022 are as follows (in thousands): Remainder of 2022 $ 158 2023 231 Total maturities 389 Less: Amount representing interest ( 9 ) Present value of operating lease liabilities $ 380 Lease costs included in the Company’s condensed consolidated statements of operations and comprehensive loss for each of the three and six months ended June 30, 2022 and 2021 were $ 0.1 million and $ 0.2 million, respectively. The Company’s operating leases had a weighted average remaining lease term of nine months and a weighted average discount rate of 5.5 % at June 30, 2022. During the reporting period, the Company was also a party to an operating lease for approximately 6,055 square feet of office space in Newton, MA (Newton Lease). Pursuant to its terms, the Newton Lease terminates on the last day of the month following the month either party notifies the other that the term of the lease shall end . The annualized base rent for the Newton Lease is approximately $ 0.3 million. Due to the short nature of the minimum lease term of the Newton Lease, the Newton Lease was not considered as an operating lease liability in accordance with ASC 842 as of June 30, 2022 . On June 15, 2022, the Company delivered to the lessor written notice of termination of the Newton Lease effective July 31, 2022.

Convertible Debt Agreement

Convertible Debt Agreement	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Convertible Debt Agreement	7. Convertible Debt Agreement On September 29, 2020, the Company entered into the Pontifax Agreement, providing up to $ 25.0 million of borrowings through three facilities of a term loan. An initial loan (“Initial Loan”) of $ 10.0 million was advanced on September 29, 2020 (“Closing Date”). An additional $ 5.0 million credit line (“Credit Line”) was available to the Company for withdrawal for a period of 12 months from the Closing Date. The Company paid a fee of 1.0 % per annum to Pontifax for the daily average amount not withdrawn under the Credit Line. A third installment loan (“Third Installment Loan”) of $ 10.0 million was conditioned upon achievement of one of the following milestones by no later than 15 months from the Closing Date: (i) the Company receives non-contingent, non-refundable gross proceeds from one or more equity financings and/or strategic partnerships, in each case consummated following the Closing Date, in the aggregate amount of at least $ 15.0 million for all such equity financings and strategic partnerships or (ii) the 65th patient has been enrolled in the URIROX-2 trial. During the three months ended December 31, 2020, the additional $ 10 million under the Third Installment Loan became available to the Company when the milestone of at least $ 15 million of gross proceeds from equity financings was achieved. The availability to withdraw amounts available under the Credit Line expired unused on September 29, 2021 and the availability to withdraw amounts available under the Third Installment Loan expired unused on December 29, 2021 . Amounts outstanding under the Pontifax Agreement have a fixed interest rate of 9.0 % per annum. The Pontifax Agreement has a term of 48 months and an interest only period of 24 months . Upon the expiration of the interest only period on September 29, 2022 , amounts borrowed will be repaid over eight equal quarterly payments of principal and interest. At its option, the Company may prepay all or part of the outstanding borrowings at any time without any prepayment premium or penalty. The Pontifax Agreement contains negative covenants restricting the Company’s activities, including limitations on dispositions, mergers or acquisitions, incurring indebtedness or liens, paying dividends or making investments and certain other business transactions. There are no financial covenants associated with the Pontifax Agreement. The obligations under the Pontifax Agreement are subject to acceleration upon the occurrence of specified events of default, including a material adverse change in the Company’s business, operations or financial or other condition. Pontifax, at its option, has the right to convert at any time any portion of the then outstanding borrowings and all accrued but unpaid interest into shares of the Company’s common stock, at the applicable conversion price. The conversion price for borrowings outstanding under the Pontifax Agreement is fixed at $ 4.10 per share. If the Company consummates a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction (each a “Stock Event”), then the applicable conversion price will be proportionately increased or decreased as necessary to reflect the proportionate change in shares of the Company’s common stock issued and outstanding as a result of such Stock Event. The Company has the right to convert at any time any portion of the then outstanding borrowings and all accrued but unpaid interest into shares of the Company’s common stock, at the applicable conversion price, subject to the fulfillment of both of the following conditions: (i) during a period of 30 consecutive trading days prior to the date on which the Company provides notice of the exercise of its conversion right, the closing price of the Company’s common stock was higher than 1.4 times the applicable conversion price of the term loans on at least 20 trading days, including on the trading day preceding the date on which the Company provides notice of the exercise of its conversion right, (ii) the number of shares of common stock issuable upon conversion by the Company shall not exceed the average weekly number of shares of the Company’s common stock traded on the stock market for the four weeks immediately preceding the date on which the Company provides notice of the exercise of its conversion right. The shares of the Company’s common stock issued upon conversion will be free of any restrictions and the Company is required to hold at all times a sufficient number of authorized, unreserved and unissued shares of its common stock required to settle any such conversion. The Company has reserved 1,219,512 shares of its common stock for conversion of the outstanding debt balance as of June 30, 2022. The Company evaluated the Pontifax Agreement for embedded features that require bifurcation, noting certain features were required to be bifurcated, but were concluded to be de minimis in value at June 30, 2022 and December 31, 2021. The Company determined the conversion feature was not required to be accounted for separately. The Company concluded that the embedded conversion option is not subject to separate accounting pursuant to either the cash conversion guidance or the beneficial conversion feature guidance. As part of the strategic process initiated in January 2022, the Company has held discussions with Pontifax regarding repayment of amounts outstanding under the Pontifax Agreement. Taking into consideration the available cash and cash equivalents at December 31, 2021 along with the termination of its reloxaliase program in March 2022 and its inability to raise sufficient capital to sustain its operations as of the date of this Quarterly Report, the Company determined that, consistent with the determination at December 31, 2021, it was appropriate to classify the full amount outstanding under the Pontifax Agreement as a current liability as of June 30, 2022 given the subjective acceleration of payment under the material adverse change clause. During the first quarter of 2022, the Company made voluntary repayments of principal totaling $ 5.0 million. The Company made an additional voluntary repayment of principal of $ 0.5 million in August 2022 The minimum aggregate future loan and interest payments at June 30, 2022 are as follows (in thousands): Years Ending December 31, 2022 $ 803 2023 2,760 2024 2,070 Total minimum payments $ 5,633 Less: Amount representing interest ( 633 ) Less; Discount ( 96 ) Less: Current portion ( 4,904 ) Loan payable, net of current portion $ —

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Stockholders' Equity	8. Stockholders’ Equity On May 3, 2022, the Company entered into a securities purchase agreement with an investor, pursuant to which the Company agreed to issue, in a registered direct offering, an aggregate of 2,872.1376 shares of Preferred Stock (split evenly between the Series D Convertible Preferred Stock, and Series E Convertible Preferred Stock). The Company received net proceeds of approximately $ 2.3 million from the issuance and sale of the Preferred Stock, after deducting offering expenses and placement agent fees. The shares of Preferred Stock have a stated value of $ 1,000 per share and are convertible, following the date of the issuance thereof, into an aggregate of 8,975,430 shares of common stock of the Company upon the conversion of the Series D Preferred Stock and into an aggregate of 8,975,430 shares of common stock of the Company upon the conversion of the Series E Preferred Stock, in each case, at a conversion price of $ 0.16 per share. HCW was the exclusive placement agent for this offering. On May 5, 2022, the Preferred Stock investor converted all of its Series D Preferred Stock into 8,975,430 shares of common stock, and on May 9, 2022, the Preferred Stock investor converted all of its Series E Preferred Stock into 8,975,430 shares of common stock. In a concurrent private placement, the Company also issued to the Preferred Stock investor the 2022 Common Warrants to purchase up to an aggregate of 22,438,575 shares of the Company’s common stock, at an exercise price of $ 0.1694 per share. The 2022 Common Warrants will become exercisable six months after the date of issuance, and will have a term of five years from the initial exercise date. The Company also issued to designees of HCW, in a concurrent private placement, the HCW Warrants to purchase up to 1,256,561 shares of Common Stock. The HCW Warrants are exercisable for $ 0.20 per share and will be exercisable six months after the date of issuance and have a term of five years from the commencement of sales pursuant to the registered direct offering. On July 16, 2021, the Company completed a registered direct offering, in which the Company issued and sold 17,416,096 shares of its common stock, pre-funded warrants ("2021 Pre-funded Warrants") to purchase up to an aggregate of 3,941,648 shares of its common stock in lieu of shares of common stock, and warrants ("2021 Common Warrants") to purchase up to 10,678,872 shares of the Company’s common stock through a securities purchase agreement with several healthcare-focused institutional and accredited investors. The combined price of each share of common stock and accompanying 2021 Common Warrant to purchase one-half of a share of common stock was $ 1.311 per share. The purchase price of each 2021 Pre-funded Warrant was $ 1.301 , which was the combined purchase price per share of common stock and accompanying 2021 Common Warrant to purchase one-half of a share of common stock, minus $ 0.01 . Gross proceeds of the transaction were $ 28.0 million. As a result of the registered direct offering, the Company received approximately $ 25.4 million after deducting offering costs. Each 2021 Common Warrant is exercisable for one share of the Company’s common stock at an exercise price of $ 1.25 per share. The 2021 Common Warrants are immediately exercisable and expire on July 16, 2026 . Each Pre-funded Warrant is exercisable for one share of common stock at an exercise price of $ 0.01 per share. All of the 2021 Pre-funded Warrants were exercised on July 16, 2021 . During the first quarter of 2021, the Company issued and sold 6,058,318 shares of its common stock under an At-the Market Equity Offering Sales Agreement with Cowen and Company, LLC (Cowen ATM Agreement) at a weighted average price of $ 1.99 per share for net proceeds of $ 11.7 million. The Company entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. (“B. Riley ATM Agreement”) on March 29, 2021. During the year ended December 31, 2021, the Company issued and sold a total of 4,081,338 shares of its common stock under the B. Riley ATM Agreement at a weighted average price of $ 1.11 per share for net proceeds of approximately $ 4.2 million. The Cowen ATM Agreement was terminated at the time the Company entered into the B. Riley ATM Agreement. The Company entered into another At Market Issuance Sales Agreement with B. Riley Securities, Inc. (“Updated B. Riley ATM Agreement”) on December 23, 2021. During the first quarter of 2022, the Company issued and sold 6,804,888 shares of its common stock under the Updated B. Riley ATM Agreement at a weighted average price of $ 0.62 per share for net proceeds of $ 3.9 million. The B. Riley ATM Agreement was terminated at the time the Company entered into the Updated B. Riley Agreement. The Company entered into the HCW ATM Agreement on July 8, 2022. Since that time and through the filing date of this Quarterly Report, the Company issued and sold 14,358,057 shares of its common stock under the HCW ATM Agreement at a weighted average price of $ 0.14 per share for net proceeds of approximately $ 1.9 million. The Updated B. Riley ATM Agreement was terminated at the time the Company entered into the HCW ATM Agreement. Common Stock The holders of common stock are entitled to one vote for each share held . Common stockholders are not entitled to receive dividends, unless declared by the Board of Directors. The Company has reserved for future issuances the following shares of common stock as of June 30, 2022 and December 31, 2021: June 30, December 31, Stock options and restricted stock units 11,691,089 8,372,313 Warrants 34,383,048 10,687,912 Common stock issuable upon conversion of outstanding debt 1,219,512 2,439,024 Employee stock purchase plan 306,527 306,527 Total 47,600,176 21,805,776 Warrants At June 30, 2022 the Company had 34,383,048 warrants outstanding for the purchase of shares of common stock at a weighted average exercise price of $ 0.51 . At December 31, 2021 , the Company had 10,687,912 warrants outstanding for the purchase of shares of common stock at a weighted average exercise price of $ 1.26 . 22,438,575 warrants with an exercise price of $ 0.1694 and 1,256,561 warrants with an exercise price of $ 0.20 expire May 3, 2027 . 10,678,872 w arrants with an exercise price of $ 1.25 expire on July 16, 2026 . 9,040 warrants with an exercise price of $ 11.06 expire on May 1, 2026 . Preferred Stock On July 12, 2022, the Company entered into a Subscription and Investment Representation Agreement (the “Subscription Agreement”) with a single accredited investor (the “Subscriber”), pursuant to which the Company agreed to issue and sell 100 shares of the Company’s Series F Non-Convertible Preferred Stock, par value $ 0.001 per share (the “Series F Non-Convertible Preferred Stock”), to the Subscriber for $ 100.00 in cash. The sale was completed and settled on July 12, 2022. The Subscription Agreement contains customary representations and warranties and certain indemnification rights and obligations of the parties. The Series F Non-Convertible Preferred Stock is not convertible into shares of the Company’s common stock or any other class or series of stock of the Company. In the event of any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the holders of Series F Non-Convertible Preferred Stock shall be entitled to receive, in priority to any distributions to the holders of Common Stock, out of the assets, whether capital or surplus, of the Company an amount equal to $ 0.01 per share, or $ 1.00 in the aggregate. The holder of the Series F Non-Convertible Preferred Stock will not be entitled to receive dividends of any kind.

Stock Incentive Plan

Stock Incentive Plan	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Incentive Plans	9. Stock Incentive Plans On October 31, 2017 , the Company adopted the 2017 Stock Option and Incentive Plan (“2017 Plan”). Upon the adoption of the 2017 Plan, no further grants would be made under the 2011 Stock Incentive Plan (“2011 Plan”). The 2017 Plan initially provided for the grant of awards for 2,038,021 shares of common stock. In addition to the shares available for grant under the 2017 Plan, shares underlying any awards outstanding under the 2011 Plan as of October 31, 2017 that are cancelled, forfeited or otherwise terminated without being exercised will be available for future grant under the 2017 Plan. The 2017 Plan also provides that an additional number of shares will automatically be added to the shares authorized for issuance under the 2017 Plan on January 1 of each year. The number of shares added each year will be equal to the lesser of: (i) 4 % of the outstanding shares on the immediately preceding December 31 or (ii) such amount as determined by the Compensation Committee of the registrant’s Board of Directors. On January 1, 2020, 2021 and 2022, the shares available for grant under the 2017 Plan were automatically increased by 989,400 , 2,032,854 and 3,318,776 shares, respectively. All of the Company’s employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock units (“RSUs”), and other share-based awards under the terms of the 2017 Plan. As of June 30, 2022 , 3,016,640 shares of common stock were available for future grant under the 2017 Plan. On January 22, 2021, the Company adopted the 2021 Inducement Equity Plan (“2021 Plan”). The 2021 Plan provides for the grant of awards for 1,600,000 shares of common stock. The purpose of the 2021 plan is to enable the Company to grant equity awards to induce highly qualified prospective officers and employees who are not currently employed by the Company to accept employment and provide them with an equity interest in the Company. The Company is utilizing the 2021 Plan for awards the Company may make without stockholder approval as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market, Inc. As of June 30, 2022 , 1,145,000 shares of common stock were available for future grant under the 2021 Plan. All stock option grants are nonstatutory stock options except option grants to employees (including officers and directors) intended to qualify as incentive stock options under the Internal Revenue Code of 1986, as amended. Incentive stock options may not be granted at less than the fair market value of the Company’s common stock on the date of grant, as determined in good faith by the Board of Directors at its sole discretion. Nonqualified stock options may be granted at an exercise price established by the Board of Directors at its sole discretion (which has not been less than fair market value on the date of grant) and the vesting periods may vary. Vesting periods are generally four years and are determined by the Board of Directors or a delegated subcommittee. Stock options become exercisable as they vest. Options granted under the 2011 Plan, 2017 Plan and 2021 Plan expire no more than 10 years from the date of grant. Stock-based compensation expense included in the Company’s statements of operations and comprehensive loss is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 135 $ 303 $ 305 $ 550 General and administrative 425 657 872 1,277 Total $ 560 $ 960 $ 1,177 $ 1,827 The fair value of each stock option granted to employees and directors during the three and six months ended June 30, 2021 was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions: Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Risk-free interest rate 0.9 %- 1.4 % 0.4 %- 1.4 % Expected dividend yield —% —% Expected term (in years) 5.4 - 7.0 5.0 - 7.0 Expected volatility 93 %- 94 % 93 %- 94 % The Company did no t grant any stock options during the three and six months ended June 30, 2022. A summary of the stock option activity under the 2011, 2017 and 2021 Plans during the six months ended June 30, 2022 is as follows: Shares Weighted- Weighted- Aggregate Outstanding at December 31, 2021 6,765,837 $ 2.81 7.6 $ 3 Granted — — Exercised — — Forfeited ( 1,316,712 ) 2.54 Expired ( 13,176 ) 0.42 Outstanding at June 30, 2022 5,435,949 2.88 7.0 $ — Exercisable at June 30, 2022 3,417,270 $ 3.31 6.2 $ — As of June 30, 2022 , total unrecognized stock-based compensation expense relating to unvested stock options was $ 3.1 million. This amount is expected to be recognized over a weighted-average period of 2.2 years. Restricted Stock Units (RSUs) On February 1, 2022, the Company awarded 2,998,500 RSUs to employees of the Company as part of the Retention Plan. The RSUs vest over a three-year period ratably on July 15th and January 15th of each year following grant date. The RSUs are generally forfeited if the employment relationship terminates with the Company prior to vesting. Shares Weighted-Average Nonvested at December 31, 2021 — $ — Granted 2,998,500 0.40 Vested — — Forfeited ( 905,000 ) 0.40 Nonvested at June 30, 2022 2,093,500 $ 0.40 As of June 30, 2022 , the total remaining unrecognized compensation cost related to all nonvested RSUs amounted to $ 0.7 million. This amount is expected to be recognized over a weighted-average period of 2.5 years .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board (“FASB”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2021 and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 31, 2022. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments which are necessary to present fairly the Company’s financial position as of June 30, 2022, the results of its operations and cash flows for the three and six months ended June 30, 2022 and June 30, 2021 and cash flows for the six months ended June 30, 2022 and 2021. Such adjustments are of a normal and recurring nature. The results for the three and six months ended June 30, 2022 are not necessarily indicative of the results for the year ending December 31, 2022 or for any future period.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allena Pharmaceuticals, Inc. and its wholly owned subsidiaries Allena Pharmaceuticals Security Corporation (“Security Corporation”), which was incorporated in December 2014 , and Allena Pharmaceuticals Ireland Limited, which was incorporated in March 2017 . All intercompany transactions and balances have been eliminated.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is defined as the price that would be received upon sale of an asset or paid to transfer a liability between market participants at measurement dates. ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a three-level valuation hierarchy for instruments measured at fair value. The hierarchy is based on the transparency of inputs to the valuation of an asset or liability as of the measurement date. The hierarchy defines three levels of valuation inputs, of which the first two are considered observable and the last is considered unobservable: Level 1 inputs: Quoted prices in active markets for identical assets or liabilities. Level 2 inputs: Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. Level 3 inputs: Unobservable inputs developed using estimates or assumptions developed by the Company, which reflect those that a market participant would use in pricing the asset or liability. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The remainder of the Company’s significant accounting policies are described in the Annual Report filed on Form 10-K for the year ended December 31, 2021 that was filed with the United States Securities and Exchange Commission on March 31, 2022.
Warrants	Warrants The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (“ASC 480-10”) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock (“ASC 815-40”). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In 2020, the FASB issued ASU 2020-06, Debt -Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) , which simplifies the accounting for convertible debt and convertible preferred stock by removing the requirements to separately present certain conversion features in equity. In addition, the amendments in the ASU also simplify the guidance in ASC 815-40, Derivatives and Hedging: Contracts in Entity’s Own Equity, by removing certain criteria that must be satisfied in order to classify a contract as equity, which is expected to decrease the number of freestanding instruments and embedded derivatives accounted for as assets or liabilities. Finally, the amendments revise the guidance on calculating earnings per share, requiring use of the if-converted method for all convertible instruments and rescinding an entity’s ability to rebut the presumption of share settlement for instruments that may be settled in cash or other assets. The Company adopted ASU 2020-06 on January 1, 2022 . The adoption of ASU 2020-06 did not have a material impact on the Company's condensed consolidated financial statements.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to record expected credit losses for certain financial instruments, including trade receivables, as an allowance that reflects the entity's current estimate of credit losses expected to be incurred. For available-for-sale debt securities in unrealized loss positions, ASU 2016-13 requires allowances to be recorded instead of reducing the amortized cost of the investment. ASU 2016-13 is effective for smaller reporting companies on January 1, 2023. Early adoption is permitted. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its condensed consolidated financial statements.

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders	Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Numerator: Net loss $ ( 8,435 ) $ ( 13,972 ) $ ( 20,248 ) $ ( 25,608 ) Net loss attributable to common stockholders $ ( 8,435 ) $ ( 13,972 ) $ ( 20,248 ) $ ( 25,608 ) Denominator: Weighted-average common shares—basic and diluted 100,623,730 57,932,389 95,034,212 56,484,811 Net loss per share attributable to common $ ( 0.08 ) $ ( 0.24 ) $ ( 0.21 ) $ ( 0.45 )
Summary of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss per Share	The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares): Six Months Ended June 30, 2022 2021 Stock options 5,435,949 7,091,757 Restricted stock units 2,093,500 372,166 Warrants 34,383,048 9,040 Common stock issuable upon conversion of outstanding debt 1,219,512 2,439,024 Total 43,132,009 9,911,987

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value	The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value at June 30, 2022 and December 31, 2021, and indicates the fair value hierarchy of the valuation inputs utilized to determine such fair value (in thousands): Description June 30, Quoted Significant Significant Assets: Money market funds, included in cash and cash equivalents $ 5,589 $ 5,589 $ — $ — Total assets $ 5,589 $ 5,589 $ — $ — Liabilities: Warrant liability $ 3,645 $ — $ — $ 3,645 Total liabilities $ 3,645 $ — $ — $ 3,645 Description December 31, Quoted Significant Significant Assets: Money market funds, included in cash and cash equivalents $ 16,523 $ 16,523 $ — $ — Total assets $ 16,523 $ 16,523 $ — $ —
Summary of Black Scholes Pricing Model Assumptions Used to Record Fair Value of Warrants	A summary of the Black Scholes pricing model assumptions used to record the fair value of the warrants is as follows: June 30, 2022 May 4, 2022 Stock price $ 0.19 $ 0.14 Risk-free interest rate 3.01 % 2.93 % Expected dividend yield —% —% Expected term (in years) 4.9 - 5.4 5.0 - 5.5 Expected volatility 106 % 105 %
Summary of Change in Level 3 Warrant Liability	The following table reflects the change in the Company’s Level 3 Warrant liability for the six months ended June 30, 2022 (in thousands): Fair value of warrant liability as of the beginning of the period $ — Issuance of warrants 2,622 Change in fair value 1,023 Fair value of warrant liability as of the end of the period $ 3,645

Accrued Expenses (Tables)

Accrued Expenses (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consist of the following (in thousands): June 30, December 31, Payroll and employee-related expenses $ 295 $ 371 Third-party research and development expenses 2,260 3,195 Professional fees 184 677 Loan interest 112 227 Other 19 10 Total accrued expenses $ 2,870 $ 4,480

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2022
ASC 842
Operating Leased Assets [Line Items]
Schedule of Maturities of Operating Lease Liabilities	Maturities of the Company’s operating lease liabilities in accordance with ASC 842 as of June 30, 2022 are as follows (in thousands): Remainder of 2022 $ 158 2023 231 Total maturities 389 Less: Amount representing interest ( 9 ) Present value of operating lease liabilities $ 380

Convertible Debt Agreement (Tab

Convertible Debt Agreement (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Summary of Minimum Aggregate Future Loan and Interest Payments	The minimum aggregate future loan and interest payments at June 30, 2022 are as follows (in thousands): Years Ending December 31, 2022 $ 803 2023 2,760 2024 2,070 Total minimum payments $ 5,633 Less: Amount representing interest ( 633 ) Less; Discount ( 96 ) Less: Current portion ( 4,904 ) Loan payable, net of current portion $ —

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Summary of Shares of Common Stock Reserved	The Company has reserved for future issuances the following shares of common stock as of June 30, 2022 and December 31, 2021: June 30, December 31, Stock options and restricted stock units 11,691,089 8,372,313 Warrants 34,383,048 10,687,912 Common stock issuable upon conversion of outstanding debt 1,219,512 2,439,024 Employee stock purchase plan 306,527 306,527 Total 47,600,176 21,805,776

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2022
Summary of Stock-based Compensation Expense	Stock-based compensation expense included in the Company’s statements of operations and comprehensive loss is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 135 $ 303 $ 305 $ 550 General and administrative 425 657 872 1,277 Total $ 560 $ 960 $ 1,177 $ 1,827
Summary of Stock Option Activity	A summary of the stock option activity under the 2011, 2017 and 2021 Plans during the six months ended June 30, 2022 is as follows: Shares Weighted- Weighted- Aggregate Outstanding at December 31, 2021 6,765,837 $ 2.81 7.6 $ 3 Granted — — Exercised — — Forfeited ( 1,316,712 ) 2.54 Expired ( 13,176 ) 0.42 Outstanding at June 30, 2022 5,435,949 2.88 7.0 $ — Exercisable at June 30, 2022 3,417,270 $ 3.31 6.2 $ —
Restricted Stock Units (RSUs)
Summary of Nonvested RSUs	Shares Weighted-Average Nonvested at December 31, 2021 — $ — Granted 2,998,500 0.40 Vested — — Forfeited ( 905,000 ) 0.40 Nonvested at June 30, 2022 2,093,500 $ 0.40
Employees and Directors
Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options	The fair value of each stock option granted to employees and directors during the three and six months ended June 30, 2021 was estimated on the date of grant using the Black-Scholes option-pricing model, with the following range of assumptions: Three Months Ended June 30, 2021 Six Months Ended June 30, 2021 Risk-free interest rate 0.9 %- 1.4 % 0.4 %- 1.4 % Expected dividend yield —% —% Expected term (in years) 5.4 - 7.0 5.0 - 7.0 Expected volatility 93 %- 94 % 93 %- 94 %

Nature of Business - Additional

Nature of Business - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

6 Months Ended

Jul. 08, 2022

May 03, 2022

Jan. 28, 2022

Jul. 16, 2021

Aug. 31, 2022

Mar. 31, 2022

Mar. 31, 2022

Jun. 30, 2022

Jun. 30, 2021

Aug. 04, 2022

May 09, 2022

May 05, 2022

Dec. 31, 2021

Class of Stock [Line Items]

Accumulated deficit

$ (266,700)

$ (246,452)

Cash and cash equivalents

$ 6,589

$ 29,988

Directors' & Officers' run off insurance amount

$ 6,800

Restructuring charges, number of workforce headcount reduction percentage

40%

Preferred stock issued

2,872

0

Preferred stock par value

$ 0.001

$ 0.001

Exercise price of warrants

$ 0.51

1.26

Net proceeds after deducting estimated offering costs

$ 3,944

$ 13,464

Common stock, par value

$ 0.001

$ 0.001

Loan and Security Agreement | Pontifax

Class of Stock [Line Items]

Voluntary principal repayments

$ 500

$ 5,000

Outstanding principal balance

$ 5,000

$ 5,000

$ 4,500

$ 10,000

Retention Plan

Class of Stock [Line Items]

Retention agreement received salary adjustment percentage

6.50%

RSUs granted

2,998,500

Employees retention payment

$ 3,000

Percentage of amount employee to repay for resigns or terminated

50%

Securities Purchase Agreement

Class of Stock [Line Items]

Preferred stock issued

2,872.1376

Preferred stock par value

$ 1,000

Net proceeds from issuance of preferred stock

$ 2,300

Conversion price

$ 16

Securities Purchase Agreement | Series D Preferred Stock

Class of Stock [Line Items]

Preferred stock par value

$ 0.001

Conversion of preferred stock

8,975,430

8,975,430

Securities Purchase Agreement | Series E Preferred Stock

Class of Stock [Line Items]

Preferred stock par value

$ 0.001

Conversion of preferred stock

8,975,430

8,975,430

Conversion price

$ 0.16

At Market Issuance Sales Agreement

Class of Stock [Line Items]

Common stock shares issued and sold

4,081,338

At Market Issuance Sales Agreement | Updated B. Riley ATM Agreement.

Class of Stock [Line Items]

Common stock shares issued and sold

6,804,888

Weighted average price of common stock shares sold and issued

$ 0.62

Net proceeds after deducting estimated offering costs

$ 3,900

HCW Warrants

Class of Stock [Line Items]

Warrant issued

1,256,561

Exercise price of warrants

$ 0.20

Warrant term

5 years

2022 Common Warrants

Class of Stock [Line Items]

Warrant issued

22,438,575

Exercise price of warrants

$ 0.1694

Warrant term

5 years

Subsequent Event

Class of Stock [Line Items]

Common stock, par value

$ 0.001

Subsequent Event | HCW ATM Agreement

Class of Stock [Line Items]

Common stock shares issued and sold

14,358,057

Weighted average price of common stock shares sold and issued

$ 0.14

Net proceeds after deducting estimated offering costs

$ 1,900

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022
ASU 2020-06
Summary Of Significant Accounting Policies [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2022
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect	false
Allena Pharmaceuticals Ireland Limited
Summary Of Significant Accounting Policies [Line Items]
Entity incorporated date	2017-03
Subsidiaries
Summary Of Significant Accounting Policies [Line Items]
Entity incorporated date	2014-12

Net Loss per Share - Summary of

Net Loss per Share - Summary of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator:
Net loss	$ (8,435)	$ (13,972)	$ (20,248)	$ (25,608)
Net loss attributable to common stockholders	$ (8,435)	$ (13,972)	$ (20,248)	$ (25,608)
Denominator:
Weighted-average common share outstanding-basic	100,623,730	57,932,389	95,034,212	56,484,811
Weighted-average common share outstanding-diluted	100,623,730	57,932,389	95,034,212	56,484,811
Net loss per share attributable to common stockholders-diluted	$ (0.08)	$ (0.24)	$ (0.21)	$ (0.45)
Net loss per share attributable to common stockholders-basic	$ (0.08)	$ (0.24)	$ (0.21)	$ (0.45)

Net Loss per Share - Summary _2

Net Loss per Share - Summary of Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss per Share (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of loss per share	43,132,009	9,911,987
Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of loss per share	5,435,949	7,091,757
Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of loss per share	2,093,500	372,166
Convertible Debt Securities Member
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of loss per share	34,383,048	9,040
Warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of loss per share	1,219,512	2,439,024

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Total assets	$ 5,589	$ 16,523
Liabilities:
Warrant liability	3,645
Total liabilities	3,645
Level 1
Assets:
Total assets	5,589	16,523
Level 3
Liabilities:
Warrant liability	3,645
Total liabilities	3,645
Money market funds, included in cash and cash equivalents
Assets:
Money market funds, included in cash and cash equivalents	5,589	16,523
Money market funds, included in cash and cash equivalents | Level 1
Assets:
Money market funds, included in cash and cash equivalents	$ 5,589	$ 16,523

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021	May 04, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in valuation methods or transfers	$ 0	$ 0
Transfers within fair value hierarchy	$ 0	$ 0
2022 Common Warrants and HCW Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant issued			23,695,136

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Black Scholes Pricing Model Assumptions Used to Record Fair Value of Warrants (Details) - Level 3	Jun. 30, 2022	May 04, 2022
Stock Price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.19	0.14
Risk-free Interest Rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	0.0301	0.0293
Expected Term | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term	4 years 10 months 24 days	5 years
Expected Term | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term	5 years 4 months 24 days	5 years 6 months
Expected Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, measurement input	1.06	1.05

Fair Value Measurements - Sum_3

Fair Value Measurements - Summary of Change in Level 3 Warrant Liability (Details) - Level 3 $ in Thousands	6 Months Ended
	Jun. 30, 2022 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Issuance of warrants	$ 2,622
Change in fair value	1,023
Fair value of warrant liability as of the end of the period	$ 3,645

Accrued Expenses - Schedule of

Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Payroll and employee-related expenses	$ 295	$ 371
Third-party research and development expenses	2,260	3,195
Professional fees	184	677
Loan interest	112	227
Other	19	10
Total accrued expenses	$ 2,870	$ 4,480

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) ft²	Jun. 30, 2021 USD ($)
Operating Leased Assets [Line Items]
Lease costs	$ 0.1	$ 0.1	$ 0.2	$ 0.2
Operating lease, weighted average remaining lease term	9 months		9 months
Operating lease, weighted average discount rate	5.50%		5.50%
Sudbury, MA
Operating Leased Assets [Line Items]
Rentable office space under operating lease | ft²			11,691
Base rent for office space			$ 0.3
Operating lease expiration date			Feb. 28, 2026
Right to terminate description			The Company has a one-time option to cancel the lease effective February 28, 2023 for any reason or no reason at all
Newton, MA
Operating Leased Assets [Line Items]
Rentable office space under operating lease | ft²			6,055
Base rent for office space			$ 0.3
Right to terminate description			the Newton Lease terminates on the last day of the month following the month either party notifies the other that the term of the lease shall end

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details) - ASC 842 $ in Thousands	Jun. 30, 2022 USD ($)
Lessee Lease Description [Line Items]
Remainder of 2022	$ 158
2023	231
Total maturities	389
Less: Amount representing interest	(9)
Present value of operating lease liabilities	$ 380

Convertible Debt Agreement - Ad

Convertible Debt Agreement - Additional Information (Details)		1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 29, 2020 USD ($) TradingDay Facility Installment $ / shares	Aug. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2022 USD ($) shares	Dec. 31, 2021 USD ($) shares
Debt Instrument [Line Items]
Shares of common stock reserved for future issuances | shares					47,600,176	21,805,776
Common Stock Issuable Upon Conversion of Outstanding Debt
Debt Instrument [Line Items]
Shares of common stock reserved for future issuances | shares					1,219,512	2,439,024
Loan and Security Agreement
Debt Instrument [Line Items]
Debt instrument, terms of conversion description					The Company has the right to convert at any time any portion of the then outstanding borrowings and all accrued but unpaid interest into shares of the Company’s common stock, at the applicable conversion price, subject to the fulfillment of both of the following conditions: (i) during a period of 30 consecutive trading days prior to the date on which the Company provides notice of the exercise of its conversion right, the closing price of the Company’s common stock was higher than 1.4 times the applicable conversion price of the term loans on at least 20 trading days, including on the trading day preceding the date on which the Company provides notice of the exercise of its conversion right, (ii) the number of shares of common stock issuable upon conversion by the Company shall not exceed the average weekly number of shares of the Company’s common stock traded on the stock market for the four weeks immediately preceding the date on which the Company provides notice of the exercise of its conversion right.
Debt instrument conversion threshold consecutive trading days | TradingDay	30
Loan and Security Agreement | Minimum
Debt Instrument [Line Items]
Debt instrument conversion threshold trading days | TradingDay	20
Loan and Security Agreement | Pontifax
Debt Instrument [Line Items]
Loan agreement, maximum borrowing capacity	$ 25,000,000
Number of term loan facilities | Facility	3
Fixed interest rate on loan amounts outstanding	9%
Loan and security agreement, term	48 months
Loan and security agreement, interest only payment period	24 months
Expiration of interest only period	Sep. 29, 2022
Loan and security agreement, number of quarterly payments | Installment	8
Loan and security agreement, frequency of payments					quarterly
Conversion price for borrowings outstanding | $ / shares	$ 4.10
Debt instrument, terms of conversion description					Pontifax, at its option, has the right to convert at any time any portion of the then outstanding borrowings and all accrued but unpaid interest into shares of the Company’s common stock, at the applicable conversion price. The conversion price for borrowings outstanding under the Pontifax Agreement is fixed at $4.10 per share. If the Company consummates a stock split, stock combination, reclassification, payment of stock dividend, recapitalization or other similar transaction (each a “Stock Event”), then the applicable conversion price will be proportionately increased or decreased as necessary to reflect the proportionate change in shares of the Company’s common stock issued and outstanding as a result of such Stock Event.
Voluntary principal repayments		$ 500,000	$ 5,000,000
Outstanding principal balance			$ 5,000,000		$ 4,500,000	$ 10,000,000
Loan and Security Agreement | Pontifax | Initial Loan
Debt Instrument [Line Items]
Loan agreement, advanced amount	$ 10,000,000
Loan and Security Agreement | Pontifax | Credit Line
Debt Instrument [Line Items]
Loan agreement, remaining borrowing capacity	$ 5,000,000
Loan and security agreement, percentage fee paid	1%
Unused credit facility expiration date	Sep. 29, 2021
Loan and Security Agreement | Pontifax | Third Installment Loan
Debt Instrument [Line Items]
Loan and security agreement, available borrowing capacity subject to achievement of milestones	$ 10,000,000			$ 10,000,000
Non-contingent, non-refundable gross proceeds from one or more equity financings and/or strategic partnerships	$ 15,000,000			$ 15,000,000
Unused credit facility expiration date	Dec. 29, 2021

Convertible Debt Agreement - Su

Convertible Debt Agreement - Summary of Minimum Aggregate Future Loan and Interest Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2022	$ 803
2023	2,760
2024	2,070
Total minimum payments	5,633
Less: Amount representing interest	(633)
Less: Discount	(96)
Less: Current portion	$ (4,904)	$ (9,852)

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended		6 Months Ended
	Jul. 12, 2022	Jul. 08, 2022	May 03, 2022	Dec. 31, 2021	Jul. 16, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	May 09, 2022	May 05, 2022
Class of Stock [Line Items]
Net proceeds after deducting offering costs								$ 3,944	$ 13,464
Each warrant exercisable shares				10,687,912				34,383,048
Exercise price of warrants				$ 1.26				$ 0.51
Common stock, voting rights								one vote for each share held
Preferred stock issued				0				2,872
Net proceeds from issuance and sale of preferred stock								$ 2,251
Preferred stock stated value per share				$ 0.001				$ 0.001
At Market Issuance Sales Agreement
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares					4,081,338
Securities Purchase Agreement
Class of Stock [Line Items]
Preferred stock issued			2,872.1376
Preferred stock stated value per share			$ 1,000
Conversion price			16
Warrants Expire on July 16, 2026
Class of Stock [Line Items]
Exercise price of warrants								$ 1.25
Warrants exercisable shares								10,678,872
Warrants expiration date								Jul. 16, 2026
Warrants Expire on May 1, 2026
Class of Stock [Line Items]
Exercise price of warrants								$ 11.06
Warrants exercisable shares								9,040
Warrants expiration date								May 01, 2026
Common Warrants
Class of Stock [Line Items]
Exercise price of warrants			$ 0.1694
Warrant issued			22,438,575
Warrant term			5 years
HCW Warrants
Class of Stock [Line Items]
Exercise price of warrants			$ 0.20
Warrants expiration date			May 03, 2027
Warrant issued			1,256,561
Warrant term			5 years
Direct Offering
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares					17,416,096
Maximum aggregate warrant to purchase number of shares of common stock					10,678,872
Combined price of each share of common stock and accompanying warrant to purchase one-half price per share					$ 1.311
Net proceeds after deducting offering costs					$ 25,400
Difference in combined price of each share of common stock and accompanying warrant and purchase price of prefunded warrant per share					$ 0.01
Gross proceeds of the transaction					$ 28,000
Each warrant exercisable shares					1
Warrant exercisable date					Jul. 16, 2026
Exercise price of warrants					$ 1.25
Direct Offering | 2021 Pre-Funded Warrant
Class of Stock [Line Items]
Maximum aggregate warrant to purchase number of shares of common stock					3,941,648
Purchase price of warrant					$ 1.301
Each warrant exercisable shares					1
Warrant exercisable date					Jul. 16, 2021
Exercise price of warrants					$ 0.01
Series D and E Convertible Preferred Stock | Securities Purchase Agreement
Class of Stock [Line Items]
Preferred stock issued			2,872.1376
Net proceeds from issuance and sale of preferred stock			$ 2,300
Preferred stock stated value per share			$ 1,000
Series D Preferred Stock | Securities Purchase Agreement
Class of Stock [Line Items]
Preferred stock stated value per share			$ 0.001
Conversion of preferred stock			8,975,430								8,975,430
Series E Preferred Stock | Securities Purchase Agreement
Class of Stock [Line Items]
Preferred stock stated value per share			$ 0.001
Conversion of preferred stock			8,975,430							8,975,430
Conversion price			$ 0.16
Series F Non-Convertible Preferred Stock | Subsequent Event
Class of Stock [Line Items]
Preferred stock stated value per share	$ 0.001
Conversion of preferred stock	100
Convertible preferred stock shares issued for cash	$ 100,000
Preferred stock, Liquidation preference per share	$ 0.01
Preferred stock, liquidation preference aggregate value	$ 1,000
Cowen ATM Agreement
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares							6,058,318
Net proceeds after deducting offering costs							$ 11,700
Weighted average price of common stock shares sold and issued							$ 1.99
B. Riley ATM Agreement | At Market Issuance Sales Agreement
Class of Stock [Line Items]
Net proceeds after deducting offering costs				$ 4,200
Weighted average price of common stock shares sold and issued				$ 1.11
Updated B. Riley ATM Agreement. | At Market Issuance Sales Agreement
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares						6,804,888
Net proceeds after deducting offering costs						$ 3,900
Weighted average price of common stock shares sold and issued						$ 0.62
HCW ATM Agreement | Subsequent Event
Class of Stock [Line Items]
Issuance of common stock, net of issuance costs, shares		14,358,057
Net proceeds after deducting offering costs		$ 1,900
Weighted average price of common stock shares sold and issued		$ 0.14

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Shares of Common Stock Reserved (Details) - shares	Jun. 30, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Shares of common stock reserved for future issuances	47,600,176	21,805,776
Stock Options and Restricted Stock Units
Class of Stock [Line Items]
Shares of common stock reserved for future issuances	11,691,089	8,372,313
Warrants
Class of Stock [Line Items]
Shares of common stock reserved for future issuances	34,383,048	10,687,912
Common Stock Issuable Upon Conversion of Outstanding Debt
Class of Stock [Line Items]
Shares of common stock reserved for future issuances	1,219,512	2,439,024
Employee Stock Purchase Plan
Class of Stock [Line Items]
Shares of common stock reserved for future issuances	306,527	306,527

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Information (Details) - USD ($) $ in Millions						3 Months Ended	6 Months Ended	12 Months Ended
	Feb. 01, 2022	Jan. 01, 2022	Jan. 01, 2021	Jan. 01, 2020	Oct. 31, 2017	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2020	Jan. 22, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of stock options granted						0
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based award, vesting period	3 years
Unrecognized stock-based compensation expense, weighted average period for recognition							2 years 6 months
RSUs granted	2,998,500						2,998,500
Share-based payment arrangement, unvested award, unrecognized, amount							$ 0.7
2011 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant					0
2017 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock option grant effective date					Oct. 31, 2017
Share based award, description							Upon the adoption of the 2017 Plan, no further grants would be made under the 2011 Stock Incentive Plan (“2011 Plan”). The 2017 Plan initially provided for the grant of awards for 2,038,021 shares of common stock. In addition to the shares available for grant under the 2017 Plan, shares underlying any awards outstanding under the 2011 Plan as of October 31, 2017 that are cancelled, forfeited or otherwise terminated without being exercised will be available for future grant under the 2017 Plan. The 2017 Plan also provides that an additional number of shares will automatically be added to the shares authorized for issuance under the 2017 Plan on January 1 of each year. The number of shares added each year will be equal to the lesser of: (i) 4% of the outstanding shares on the immediately preceding December 31 or (ii) such amount as determined by the Compensation Committee of the registrant’s Board of Directors. On January 1, 2020, 2021 and 2022, the shares available for grant under the 2017 Plan were automatically increased by 989,400, 2,032,854 and 3,318,776 shares, respectively.
Percentage criteria for additional shares granted					4%
Additional shares available for grant		3,318,776	2,032,854	989,400
2017 Plan | Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for future grant							3,016,640
Stock-based award, vesting period								4 years
2017 Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant					2,038,021
2021 Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant									1,600,000
Shares available for future grant							1,145,000
2011, 2017 and 2021 Plans
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to unvested employee stock options							$ 3.1
Unrecognized stock-based compensation expense, weighted average period for recognition							2 years 2 months 12 days
2011, 2017 and 2021 Plans | Stock Options | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based award, expiration period							10 years

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 560	$ 960	$ 1,177	$ 1,827
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	135	303	305	550
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 425	$ 657	$ 872	$ 1,277

Stock Incentive Plans - Schedul

Stock Incentive Plans - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options (Details) - Stock Options - Employees and Directors	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.90%	0.40%
Risk-free interest rate, maximum	1.40%	1.40%
Expected volatility, minimum	93%	93%
Expected volatility, maximum	94%	94%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 4 months 24 days	5 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	7 years	7 years

Stock Incentive Plans - Summa_2

Stock Incentive Plans - Summary of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Granted	0
2011, 2017 and 2021 Plans
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Outstanding, Beginning balance	6,765,837	6,765,837
Shares, Forfeited		(1,316,712)
Shares, Expired		(13,176)
Shares, Outstanding, Ending balance		5,435,949	6,765,837
Shares, Exercisable		3,417,270
Weighted-Average Exercise Price, Outstanding, Beginning balance	$ 2.81	$ 2.81
Weighted-Average Exercise Price, Forfeited		2.54
Weighted-Average Exercise Price, Expired		0.42
Weighted-Average Exercise Price, Outstanding, Ending balance		2.88	$ 2.81
Weighted-Average Exercise Price, Exercisable		$ 3.31
Weighted-Average Remaining Contractual Life (in years), Outstanding		7 years	7 years 7 months 6 days
Weighted-Average Remaining Contractual Life (in years), Exercisable		6 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding		$ 0	$ 3
Aggregate Intrinsic Value, Exercisable		$ 0

Stock Incentive Plans - Summa_3

Stock Incentive Plans - Summary of Nonvested RSUs (Details) - Restricted Stock Units (RSUs) - $ / shares		6 Months Ended
	Feb. 01, 2022	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, Outstanding, Beginning balance		0
Shares, Granted	2,998,500	2,998,500
Shares, Forfeited		(905,000)
Shares, Outstanding, Ending balance		2,093,500
Weighted-Average Grant Date Fair Value, Outstanding, Beginning balance		$ 0
Weighted-Average Grant Date Fair Value, Granted		0.40
Weighted-Average Grant Date Fair Value, Forfeited		0.40
Weighted-Average Grant Date Fair Value, Outstanding, Ending balance		$ 0.40